Anzeige
Mehr »
Freitag, 13.06.2025 - Börsentäglich über 12.000 News
Anleger aufgepasst: Weltbank setzt jetzt ein neues Signal für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
150 Leser
Artikel bewerten:
(0)

Titian Software; Labguru: Survey of 150+ Scientists by Titian Software & Labguru (BioData) Reveals Data Challenges in Lab Digitization

Enhanced Lab Data Management and AI Critical to Labs of the Future

LONDON, June 12, 2025 /PRNewswire/ -- Data stands at the centre of transformation in today's digital labs - both as a major obstacle and a driving force for innovation, according to a survey of more than 150 scientists from Titian Software and Labguru.

Titian Software Labguru logo

Data overload and management were identified as the most significant challenges impacting lab operations. This same data deluge offers a powerful opportunity: respondents cited AI's potential to manage and extract insights from the vast volumes of data generated by experiments, instruments, and other sources as its most valuable future role. This duality highlights data as not just a pain point, but the foundation for unlocking the next wave of AI-driven advances in the lab.

Titian Software, which delivers the Mosaic sample management solution, and Labguru a leading lab LIMS, ELN, inventory, and data management platform, have released the results of their latest survey looking to the future of digital lab operations in the life sciences industry.

While machine learning and AI are expected to be major drivers of transformation in lab operations, the reality is that many labs aren't quite ready to fully harness its potential. Foundational issues remain, with inventory management and the automation of manual processes taking precedence. In fact, 65% of survey respondents identified inventory management-specifically of reagents and supplies-as the top technology they're interested in adopting. A strong majority-77% of respondents-believe automation will be the primary driver of change by 2026, underscoring the urgent need to address manual processes before the broader adoption of AI and machine learning.

The results signal the pressing need to address operational inefficiencies before labs can scale into more advanced technologies. The results were consistent across every type of lab, from big pharma to start-up. Despite growing interest in next-generation tools like AI and robotics, only 15% of labs claim to be fully digitized, and half still rely heavily on manual processes.

While 45% of respondents plan to implement next-generation lab technologies like AI within the next two years, a significant portion-25%-have no near-term plans or anticipate needing more than five years. This gap highlights a critical period of transition, where foundational improvements must be prioritized before the full promise of AI can be realized.

AI's greatest promise lies in making sense of the overwhelming volume and complexity of lab data. Nearly a quarter of respondents (24%) identified managing data from lab experiments and instruments as the most significant role AI will play in lab operations over the next five years. With 54% citing data overload and management as a key challenge driving change, the need is clear. It's not just the quantity of data that's straining labs-it's the complexity across diverse modalities, creating added pressure around storage, automation, acquisition, compliance, and regulatory requirements.

The life sciences industry is poised for a major evolution, as AI moves from a promising concept to a practical necessity in digital lab operations.

While organizations widely recognize AI's potential to improve efficiency, accelerate discovery, and make sense of complex data, digital maturity remains uneven-and barriers like data silos and scepticism around AI outputs persist.

"Labs today are generating more data than ever before, but without the right systems in place, that data becomes a burden instead of a benefit," said Keith Hale, Group Chief Executive Officer at Titian Software and Labguru. "Better data practices and smarter sample and inventory management are essential not only for improving day-to-day operations but also for setting the stage for more advanced capabilities. AI cannot deliver real, meaningful benefit without connected and well-managed data. That is where we come in. By helping labs streamline and structure their operations and data management today, we can enable the power of AI to transform the labs of tomorrow."

ABOUT THE SURVEY

In January 2025, Titian Software and Labguru surveyed the life sciences industry to understand the trends and innovations that matter most in digital lab operations. 155 people completed the survey. These findings represent the current state of automation and data management and the evolution of AI in life science and its potential impact in lab operations. Survey respondent breakdown by organization type:

  • 26% from large pharma/biotech (>5,000 employees)
  • 12% from mid-size pharma/biotech (500-5,00 employees)
  • 29% from small (start-up) pharma/biotech (<500 employees)
  • 4% from CRO (Contract Research Organization)
  • 21% from academic institution
  • 8% from other organizations

Other organization types specified included: Research Lab for Manufacturing, Research and Consulting Lab, Chemical Company, small startup, carbon capture tech development and government.

ABOUT TITIAN SOFTWARE AND LABGURU

Titian Software and Labguru are two leading providers of laboratory data management solutions for life science research and industry. Following the recent acquisition of both companies by Battery Ventures, Labguru has joined forces with Titian Software to create a global organization delivering sample management, inventory management, electronic lab notebook (ELN) and laboratory information management system (LIMS) capabilities, as part of the goal to accelerate the future of digital lab operations. Together, the companies already serve more than 45,000 scientists and manage vast repositories of over one billion samples across 900+ companies and universities, including eight of the top 10 biopharma companies.

Media Contact

Amy Kenigsberg
K2 Global Communications
http://k2-gc.com/
amy@k2-gc.com

Logo - https://mma.prnewswire.com/media/2448578/Titian_Software_Labguru_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/survey-of-150-scientists-by-titian-software--labguru-biodata-reveals-data-challenges-in-lab-digitization-302480215.html

© 2025 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.